SAN DIEGO, July 8, 2020 /PRNewswire/ -- Affigen's Cancer Therapeutic Patent Portfolio addresses:
The Problem: The Signature Receptor is often unique from patient-to-patient necessitating a new drug for each patient within a clinically relevant time frame.
The Solution: The Signature Platform enables the production of patient-specific therapies against Signature Receptors with unprecedented speed and precision.
These therapies have the potential to bring a new class of safe and effective options to patients with Cancers, Autoimmune Diseases and Lymphoproliferative Disorders
View Technology Summary
View Patent Analysis Report, Patent Prosecution Analytics & Patent PDF
View Auction Information
View Bid Submission Form
About Heritage Global Inc. www.hginc.com
Heritage Global Inc. HGBLHGP is a diversified financial services company providing acquisition, disposition, valuation and lending services for surplus and distressed assets.
About Heritage Global Patents & Trademarks
Heritage Global Patents & Trademarks is the Intellectual Property Division of Heritage Global Inc. and provides a patent monetization services via Patent Auctions and Patent Brokerage on its online monetization platform The Patent Exchange.
- Patents no longer part of strategic corporate objectives
- Patents which have never been commercialized nor developed and for which there are no plans to do so
- Unwanted patents representing ongoing renewal costs but whose market value declines with every year of non-use
- Orphan Patents acquired in mergers and acquisitions that are non-core and not needed
Contact:
Doug Berman, Managing Director
Heritage Global Patents & Trademarks
The Patent Exchange
www.patent-exchange.com
707-245-4417
243179@email4pr.com
SOURCE Heritage Global Patents & Trademarks
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.